Fibroblast Growth Factor 23, Hepatocyte Growth Factor, Interleukin-6, High-Sensitivity C-Reactive Protein and Soluble Urokinase Plasminogen Activator Receptor. Inflammation Markers in Chronic Haemodialysis Patients?

2013 ◽  
Vol 78 (3) ◽  
pp. 285-290 ◽  
Author(s):  
G. Almroth ◽  
J. Lönn ◽  
F. Uhlin ◽  
F. Nayeri ◽  
L. Brudin ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
High Sensitivity ◽  
Chronic Haemodialysis ◽  
Inflammation Markers ◽  
C Reactive Protein ◽  
Urokinase Plasminogen Activator Receptor ◽  
Reactive Protein ◽  
Plasminogen Activator Receptor ◽  
Hepatocyte Growth

scholarly journals Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Yuli Huang ◽  
Haobin Zhou ◽  
Yu Wu ◽  
You Yang ◽  
Wensheng Li ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Risk Factor ◽  
Coronary Artery ◽  
High Sensitivity ◽  
Chinese Patients ◽  
C Reactive Protein ◽  
Urokinase Plasminogen Activator Receptor ◽  
Reactive Protein ◽  
Plasminogen Activator Receptor ◽  
Artery Disease

Background. Soluble urokinase plasminogen activator receptor (suPAR) is a novel marker of chronic inflammation and is considered to be a risk factor for coronary artery disease (CAD) in Caucasians. This study investigated the role of suPAR in young Chinese patients with CAD.Methods. The study involved a total of 196 consecutive young (age ≤ 55 years) patients with angiographically proven CAD and 188 age-matched non-CAD individuals as controls. Traditional risk factors were evaluated using conventional assays, and levels of suPAR were measured by sandwich enzyme-linked immunosorbent assays.Results. Levels of suPAR were significantly correlated with age (r=0.20,P=0.04), smoking (r=0.33,P=0.008), body mass index (r=0.21,P=0.03), and high-sensitivity C-reactive protein (hs-CRP;r=0.31,P=0.01). Multivariate logistic regression analysis showed that male sex (odds ratio (OR) = 3.12; 95% confidence interval (CI) = 1.18–8.25,P=0.02), smoking (OR = 3.41, 95% CI = 1.55–7.50,P=0.002), triglyceride (OR = 1.89, 95% CI = 1.10–3.25,P=0.02), high-sensitivity C-reactive protein (OR = 1.24, 95% CI = 1.02–0.03,P=0.03), and suPAR (OR = 1.37, 95% CI = 1.09–1.72,P=0.007) were independently associated with CAD risk in young patients.Conclusions. SuPAR is a novel independent risk factor for CAD in young Chinese patients. Further studies evaluating the effect of anti-inflammatory treatment on the suPAR levels and the risk of CAD are needed.

scholarly journals Mendelian Randomization Analysis of Circulating Adipokines and C-reactive Protein on Breast Cancer Risk

2019 ◽  
Author(s):  
T Robinson ◽  
RM Martin ◽  
J Yarmolinsky
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Oestrogen Receptor ◽  
Mendelian Randomization ◽  
Genome Wide Association Studies ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Hepatocyte Growth

AbstractAdipokines and C-reactive protein (CRP) have been proposed as molecular mediators linking adiposity to breast cancer (BCa). Mendelian randomization (MR) uses genetic variants as proxies for risk factors to strengthen causal inference in observational studies. We performed a MR analysis to evaluate the causal relevance of six circulating adipokines (adiponectin, hepatocyte growth factor, interleukin-6, leptin receptor, plasminogen activator inhibitor-1, resistin) and CRP in risk of overall and oestrogen receptor-stratified BCa in up to 122,977 cases and 105,974 controls. Genetic instruments were constructed from single-nucleotide polymorphisms robustly (P<5×10−8) associated with risk factors in genome-wide association studies. In MR analyses, there was evidence for a causal effect of hepatocyte growth factor on ER- BCa (OR per SD increase:1.17, 95% CI: 1.01-1.35; P=0.035) but little evidence for effects of other adipokines or CRP on overall or oestrogen receptor-stratified BCa. Collectively, these findings do not support an important etiological role of various adipokines or CRP in BCa risk.

Hepatocyte Growth Factor Is a Better Indicator of Therapeutic Response than C-Reactive Protein within the First Day of Treatment in Pneumonia

Chemotherapy ◽  
2006 ◽  
Vol 52 (5) ◽  
pp. 260-263 ◽  
Author(s):  
Hossein Abednazari ◽  
Junyang Xu ◽  
Eva Millinger ◽  
Lars Brudin ◽  
Pia Forsberg ◽  
...  
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Therapeutic Response ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Hepatocyte Growth
Sign in / Sign up

Export Citation Format

Share Document